DK1772464T3 - Fremgangsmåder til identificering af indirekte agonister af IGF-1 - Google Patents

Fremgangsmåder til identificering af indirekte agonister af IGF-1

Info

Publication number
DK1772464T3
DK1772464T3 DK06026832T DK06026832T DK1772464T3 DK 1772464 T3 DK1772464 T3 DK 1772464T3 DK 06026832 T DK06026832 T DK 06026832T DK 06026832 T DK06026832 T DK 06026832T DK 1772464 T3 DK1772464 T3 DK 1772464T3
Authority
DK
Denmark
Prior art keywords
igf
methods
indirect agonists
identifying
identifying indirect
Prior art date
Application number
DK06026832T
Other languages
English (en)
Inventor
Michelle Schaffer
Mark Ultsch
Felix Vajdos
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1772464T3 publication Critical patent/DK1772464T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
DK06026832T 2001-02-09 2002-02-01 Fremgangsmåder til identificering af indirekte agonister af IGF-1 DK1772464T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27
PCT/US2002/003156 WO2002064627A2 (en) 2001-02-09 2002-02-01 Crystallization of igf-1

Publications (1)

Publication Number Publication Date
DK1772464T3 true DK1772464T3 (da) 2009-12-14

Family

ID=26952796

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02724908T DK1358209T3 (da) 2001-02-09 2002-02-01 Krystallisering af IGF-1
DK06026832T DK1772464T3 (da) 2001-02-09 2002-02-01 Fremgangsmåder til identificering af indirekte agonister af IGF-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02724908T DK1358209T3 (da) 2001-02-09 2002-02-01 Krystallisering af IGF-1

Country Status (20)

Country Link
US (8) US7084240B2 (da)
EP (3) EP1358209B1 (da)
JP (2) JP4489352B2 (da)
KR (1) KR100872613B1 (da)
CN (1) CN100439397C (da)
AT (2) ATE439378T1 (da)
AU (1) AU2002255508B2 (da)
BR (1) BR0207422A (da)
CA (1) CA2431033A1 (da)
DE (3) DE60233359D1 (da)
DK (2) DK1358209T3 (da)
ES (2) ES2331150T3 (da)
HK (1) HK1060138A1 (da)
HU (1) HUP0500733A3 (da)
IL (2) IL156435A0 (da)
MX (1) MXPA03007042A (da)
NZ (3) NZ526672A (da)
PL (1) PL374181A1 (da)
WO (1) WO2002064627A2 (da)
ZA (1) ZA200304900B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
ATE382364T1 (de) * 2001-09-18 2008-01-15 Bioexpertise Llc Von igf-bindungsprotein stammendes peptid
WO2004102151A2 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
EP1684705A4 (en) * 2003-11-03 2008-02-20 New Century Pharmaceuticals ALBUMIN BINDING FACILITIES FOR THE EVALUATION OF MEDICAMENTAL INTERACTION EFFECTS AND METHOD FOR ASSESSING OR DESIGNING MEDICAMENT BASED ON THEIR ALBUMIN BONDING PROPERTIES
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2006039622A2 (en) * 2004-10-01 2006-04-13 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US8350007B2 (en) 2007-08-17 2013-01-08 The Regents Of The University Of California Crystal structure of human mitoNEET protein
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
KR101417872B1 (ko) * 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체
WO2011047204A1 (en) * 2009-10-14 2011-04-21 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
US20150119394A1 (en) * 2012-03-28 2015-04-30 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor Inhibitors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
WO2015095650A1 (en) 2013-12-19 2015-06-25 Puretein Bioscience Llc. Methods for treating an animal
US20240050455A1 (en) * 2020-06-01 2024-02-15 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577276A (en) * 1897-02-16 Quarter-saver iv
US589867A (en) * 1897-09-14 Clothes-line hanger
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US5077276A (en) 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
DE3717370A1 (de) 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
DE68905203T2 (de) 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
ATE195553T1 (de) 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
ES2140463T3 (es) 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH08500123A (ja) 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
DE69630120T2 (de) 1995-06-22 2004-04-08 Biogen, Inc., Cambridge Kristalle von fragmenten von cd40-liganden und deren verwendung
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP1001991A4 (en) 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
US6410335B1 (en) 1998-01-21 2002-06-25 The Brigham And Woman's Hospital, Inc. Circulating insulin-like growth factor-I and prostate cancer risk
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2004512010A (ja) 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト
EP1399475A2 (en) 2001-06-07 2004-03-24 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
JP2009215299A (ja) 2009-09-24
MXPA03007042A (es) 2004-05-24
DK1358209T3 (da) 2007-05-07
US7354769B2 (en) 2008-04-08
KR20040064610A (ko) 2004-07-19
CN100439397C (zh) 2008-12-03
EP1801120A1 (en) 2007-06-27
US20060287235A1 (en) 2006-12-21
IL156435A (en) 2009-09-22
US7238658B2 (en) 2007-07-03
ATE349469T1 (de) 2007-01-15
CN1703425A (zh) 2005-11-30
EP1772464B1 (en) 2009-08-12
JP4489352B2 (ja) 2010-06-23
HUP0500733A3 (en) 2010-01-28
HK1060138A1 (en) 2004-07-30
NZ548359A (en) 2007-11-30
CA2431033A1 (en) 2002-08-22
EP1358209B1 (en) 2006-12-27
PL374181A1 (en) 2005-10-03
BR0207422A (pt) 2005-04-19
DE60217066T4 (de) 2010-07-01
US20060293507A1 (en) 2006-12-28
US20060281905A1 (en) 2006-12-14
US20050215477A1 (en) 2005-09-29
IL156435A0 (en) 2004-01-04
ATE439378T1 (de) 2009-08-15
WO2002064627A2 (en) 2002-08-22
ZA200304900B (en) 2005-07-27
DE60217066D1 (de) 2007-02-08
ES2331150T3 (es) 2009-12-22
ES2278020T3 (es) 2007-08-01
KR100872613B1 (ko) 2008-12-09
EP1772464A3 (en) 2007-10-03
US20020165155A1 (en) 2002-11-07
EP1358209A2 (en) 2003-11-05
AU2002255508B2 (en) 2008-04-03
US7297763B2 (en) 2007-11-20
DE60217066T2 (de) 2007-07-12
WO2002064627A3 (en) 2003-07-31
HUP0500733A2 (hu) 2005-10-28
US20060276397A1 (en) 2006-12-07
NZ526672A (en) 2006-10-27
EP1772464A2 (en) 2007-04-11
US20060287510A1 (en) 2006-12-21
US7084240B2 (en) 2006-08-01
NZ548358A (en) 2008-04-30
JP2005503329A (ja) 2005-02-03
US20060270839A1 (en) 2006-11-30
DE60233359D1 (de) 2009-09-24
US7433788B2 (en) 2008-10-07
US7596455B2 (en) 2009-09-29

Similar Documents

Publication Publication Date Title
DK1772464T3 (da) Fremgangsmåder til identificering af indirekte agonister af IGF-1
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
ATE539425T1 (de) Bereitstellung von verkehrsinformationen mit unterverknüpfungen von verknüpfungen
WO2008041953A3 (en) Dengue diagnosis and treatment
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
BRPI0413070A (pt) métodos e sistemas para entender um significado de um item de conhecimento, usando informação associada com o item de conhecimento
ATE425643T1 (de) Verfahren und system zum halten einer sitzungskontinuität
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
WO2006069023A3 (en) Assay method and apparatus with reduced sample matrix effects
DE602004019812D1 (de) Marker für neuromyelitis optica
ATE330244T1 (de) Verfahren zur schätzung der besten anfangsfokussierung
BR0116847B1 (pt) sistema de elevador, e, mÉtodo para inspecionar pelo menos uma correia em um sistema de elevador.
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
NO20052553L (no) Cobalaminanalyse.
WO2002086081A3 (en) Methods and systems for identifying proteins
MXPA04001730A (es) Metodo para determinacion de multiples analitos.
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
EP1672935A4 (en) PROCESSING PROCEDURES AFTER THE PRIVACY INFORMATION OF A TARGET USER DEVICE WAS MODIFIED
DK1224222T3 (da) Chemokinreceptor
BR0300368B1 (pt) máscara, dispositivo e método para depositar reagentes sobre um suporte analítico para amostras biológicas, método para detectar os constituintes de uma ou mais amostras biológicas por imunofixação, e, kit.
DE60226244D1 (de) Il-4 rezeptor sequenzvarianten, die mit typ i diabetes assoziiert sind
MX2021003990A (es) Metodos para detectar agonistas de ubiquitina ligasa.
AU3169599A (en) Method for screening substance promoting oligomerization of receptor protein molecules
BRPI0413610A (pt) método para a identificação de agonistas ou inibidores da proteìna quinase irs